Experts agree that new ways of working are needed if R&D is to continue producing innovative products now and in the future.
The past generation of pharmaceutical R&D is over. Life-sciences companies are facing a perfect storm of challenges: eroding margins, decreasing R&D productivity, pressure to demonstrate health outcomes and cost effectiveness, and increased scrutiny over product safety.
The classic R&D development takes far too long and is predisposed to identify failures late in the process, which is expensive. The classic model also has a tendency to bring products to the market with little or no therapeutic advantage — at the expense of true innovation.
“The time of blockbuster-driven pharmaceutical R&D is quickly drawing to a close,” says Sanjeev Wadhwa, partner and director life-sciences R&D, at Computer…
Attributes of a Transformed R&D Model
Tips for Adopting a New R&D Model
Top Trends Impacting R&D
Paul Chew, M.D. Senior VP, U.S. Chief Medical Officer/Chief Scientific Officer, Sanofi-Aventis US, a pharmaceutical company that discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. For more information, visit sanofi-aventis.us.
Terri Cooper. Principal and National Leader, Life Sciences R&D Practice, Deloitte Consulting LLP, which offers professional services across all segments of the health plan, health provider, and life-sciences industries. For more information, visit deloitte.com.
James J. DeSanti. CEO, PharmaVigilant, a SaaS company, provides broad technologies to streamline the clinical trial process for biopharmaceutical companies. For more information, visit pharmavigilant.com.
Glen de Vries. President, Medidata Solutions, a global provider of SaaS-based clinical development solutions that enhance the efficiency of clinical trials. For more information, visit mdsol.com.
Jean-Jacques Garaud, M.D. Global Head of Pharma Research and Early Development (pRED), Roche, which addresses unmet medical needs through early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring. For more information, visit roche.com.
Glenn Gormley, M.D., Ph.D. Chief Science Officer, Co-head, Research & Development, Daiichi Sankyo, and Global Head of Development, President, Daiichi Sankyo Pharma Development (DSPD), Daiichi Sankyo Inc. is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. For more information, visit dsi.com.
Devin Gross. CEO, Emmi Solutions LLC, which provides an interactive media platform that enables healthcare organizations to track patient participation, enhance the patient experience, and meet regulatory guidelines. For more information, visit emmisolutions.com.
Michael Naimoli. Worldwide Managing Director, Health and Life Sciences, Microsoft Corp., which is committed to improving health around the world through software innovation. For more information, visit microsoft.com.
Todd Reul. Director, Clinical Services, ClearTrial, which provides clinical trial operations (CTO)
software that makes the planning, forecasting, and tracking of clinical project and financial performance faster and more accurate. For more information, visit cleartrial.com.
Sheila Rocchio. VP of Marketing, PHT Corp., a provider of electronic patient reported outcome (ePRO) solutions used in clinical trials around. For more information, visit phtcorp.com.
Val Romberg. Senior VP, Research & Development, CSL Behring, which researches, develops,
manufactures, and markets biotherapies that are used to treat serious and rare conditions. For more information, visit cslbehring.com.
Sanjeev Wadhwa. Partner and Director Life-Sciences R&D, Computer Sciences Corp. (CSC) Life Sciences Practice, which provides solutions that improve the way physicians deliver services, experts conduct medical research, and institutions provide coverage. For more information, visit csc.com.